Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela G Arnold

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Breast Cancer Research and Treatment|January 16, 2021
The RAD51D c.82G>A (p.Val28Met) variant disrupts normal splicing and is associated with hereditary ovarian cancerCiyu Yang, Angela G Arnold, Amanda Catchings, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 1, 2014
Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiencyM Carolina Reyes, Angela G Arnold, Noah D Kauff, et al.
Gynecologic Oncology|August 23, 2011
Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancersDavid M Hyman, Qin Zhou, Angela G Arnold, et al.
European Journal of Human Genetics : EJHG|February 23, 2021
Resolving pathogenicity classification for the CDH1 c.[715G>A] (p.Gly239Arg) VariantZarina Yelskaya, Angela G Arnold, Vanessa J Marcell, et al.
European Journal of Human Genetics : EJHG|April 28, 2021
Correction to: Resolving pathogenicity classification for the CDH1 c.[715G>A] (p.Gly239Arg) variantZarina Yelskaya, Angela G Arnold, Vanessa J Marcell, et al.
The American Journal of Surgical Pathology|November 18, 2015
Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical OutcomesYaser R Hussein, Jennifer A Ducie, Angela G Arnold, et al.
Breast Cancer Research and Treatment|November 3, 2016
Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer familyCiyu Yang, Angela G Arnold, Magan Trottier, et al.
Gynecologic Oncology|May 15, 2012
Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinomaDavid M Hyman, Kara C Long, Edward J Tanner, et al.
Cancer|December 6, 2011
Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancerDavid M Hyman, Qin Zhou, Alexia Iasonos, et al.
JCO Precision Oncology|October 20, 2022
Germline <i>SMARCA4</i> Deletion as a Driver of Uterine Cancer: An Atypical PresentationAnastasia Navitski, Duaa H Al-Rawi, Vicky Makker, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Breast Cancer Research and Treatment|January 16, 2021
The RAD51D c.82G>A (p.Val28Met) variant disrupts normal splicing and is associated with hereditary ovarian cancerCiyu Yang, Angela G Arnold, Amanda Catchings, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 1, 2014
Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiencyM Carolina Reyes, Angela G Arnold, Noah D Kauff, et al.
Gynecologic Oncology|August 23, 2011
Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancersDavid M Hyman, Qin Zhou, Angela G Arnold, et al.
European Journal of Human Genetics : EJHG|February 23, 2021
Resolving pathogenicity classification for the CDH1 c.[715G>A] (p.Gly239Arg) VariantZarina Yelskaya, Angela G Arnold, Vanessa J Marcell, et al.
European Journal of Human Genetics : EJHG|April 28, 2021
Correction to: Resolving pathogenicity classification for the CDH1 c.[715G>A] (p.Gly239Arg) variantZarina Yelskaya, Angela G Arnold, Vanessa J Marcell, et al.
The American Journal of Surgical Pathology|November 18, 2015
Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical OutcomesYaser R Hussein, Jennifer A Ducie, Angela G Arnold, et al.
Breast Cancer Research and Treatment|November 3, 2016
Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer familyCiyu Yang, Angela G Arnold, Magan Trottier, et al.
Gynecologic Oncology|May 15, 2012
Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinomaDavid M Hyman, Kara C Long, Edward J Tanner, et al.
Cancer|December 6, 2011
Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancerDavid M Hyman, Qin Zhou, Alexia Iasonos, et al.
JCO Precision Oncology|October 20, 2022
Germline <i>SMARCA4</i> Deletion as a Driver of Uterine Cancer: An Atypical PresentationAnastasia Navitski, Duaa H Al-Rawi, Vicky Makker, et al.
Pageof 3